

These Topoisomerase-II inhibitors-type leukaemias display specific clinical and cytogenetic characteristics, such as short latency (median 18 months), monocytic phenotype and specific translocations. The potential relationship between dose, dose-intensity, pharmacological interactions with other drugs, and incidence of those SAL is yet undetermined.

**Mat. and Methods:** the data of 8 international phase III trials (7383 patients (pts), median follow-up 37–160 months) informative for anthracyclin-related SAL have been reviewed. The doses of anthracyclins used can be classified as low (Dox  $\leq$  50 mg/m<sup>2</sup>/cy or 4-Epi  $\leq$  50–60 mg/m<sup>2</sup>/cy, 1211 pts) or high (Dox  $\geq$  60 mg/m<sup>2</sup>/cy or 4-Epi 100–120 mg/m<sup>2</sup>/cy, 6172 pts).

**Results:** the observed anthracyclin-related SAL numbers regarding doses used are listed in the following table.

	Low doses Dox/4-Epi	High doses Dox/4-Epi
Total Nb Pts	11211	6172
No anthra-related SAL	1 (0.08%)	>26 (>0.4%)

These simplified data strongly suggest a dose-response relationship of anthracyclin-related leukemogenesis, which should be studied in a multifactorial model. Since early BC pts are more and more likely to receive high anthracyclin doses, a concerted and/or prospective effort is warranted to resolve these issues.

1339

POSTER

### Survival analysis of an additional therapy with oral enzymes in patients with multiple myeloma

A. Sakalova<sup>1</sup>, L. Dedik<sup>2</sup>, P.R. Bock<sup>3</sup>, J. Hanisch<sup>3</sup>, W. Schiess<sup>4</sup>. <sup>1</sup>Clinic of Haematology and Transfusion Medicine, University Hospital, Bratislava; <sup>2</sup>Faculty of Mechanical Engineering, Slovak Technical University, Bratislava, Slovakia; <sup>3</sup>IFAG Basel, Basel, Switzerland; <sup>4</sup>MUCOS Pharma, Geretsried, Germany

The objective of this study was to assess existing data on patients with Multiple Myeloma (stages I–III) treated with different therapeutic regimens – Chemotherapy alone (VMCP/MOCCA, VAD) (CH) vs. Chemotherapy and additional treatment with oral enzymes (Wobe-Mugos®E, MUCOS Pharma, Geretsried, Germany) (OE). For this a retrospective cohort analysis in parallel groups of data of all patients diagnosed and treated in the Clinic of Haematology and Transfusion Medicine, Bratislava, from 1987 to 1997 (CH 99, OE 166 patients) was performed. Aim of this analysis was to investigate the effect of OE on survival. Primary efficacy parameter was the Kaplan-Meier-estimate of survival and the median survival time for both groups. Secondary parameters were response quality and response rate during the first year, duration of first remission, and the safety of a treatment with OE.

Both groups were comparable for their demographic data, and also for disease specific data. In the OE group for disease stage III median survival was 83 months compared to 47 months in the CH group (P logrank = 0.0014), and also for stages I–III survival time was longer in the OE group; adjusted sample (P logrank = 0.0003). In stage IIIA the resp. results were 88 vs. 49 months (P logrank = 0.0040), and for patients with renal insufficiency (stage IIIB) 66 vs. 37 months (P logrank = 0.1460). Multivariate Cox regression analyses confirmed these results. Response rates are higher and duration of remission is longer in the OE group. An early remission and a long duration of the first remission is an important prognostic factor for the survival of the patient.

Oral enzymes were well tolerated with 3.6% of the patients experiencing mild to moderate gastrointestinal symptoms.

The long term additional therapy with oral enzymes in patients with multiple myeloma receiving optimised chemotherapy regimens considerably prolongs survival. In our group of 265 patients median survival prolongation depended on disease stage, and on therapy with/without OE. Progression of disease stage increases the estimated mortality risk 5 to 6 fold, whereas OE decrease the estimated mortality risk by 50 to 60%.

1340

POSTER

### Hodgkin's disease in the elderly – Less may be more

D. Feltl, J. Zámečník, P. Vitek. Institute of Radiation Oncology, Prague, Czech Republic

**Introduction:** Patients with Hodgkin's disease (HD) older than 60 years have been treated at our institute with less aggressive approach in effort to minimise the side effects of chemotherapy and radiotherapy. The aim of the study was to compare our results with the data referred elsewhere and to establish the prognostic value of assessed factors.

**Methods:** From 1973 to 1993 there were 52 elderly (older than 60 years) patients with HD treated following Prague Cooperative Group protocol, which includes a relatively mild chemotherapy regimen (COPP) and/or limited field radiation techniques. Clinical stage, histological subtype, treatment modality, accomplishment of treatment, response to treatment, disease free survival (DFS), overall survival (OS) and tolerance of treatment were assessed using a retrospective analysis.

**Results:** Of the eligible 52 patients 30 (57.5%) achieved complete remission, 19 (36.5%) partial remission and 3 (6%) had a progressive disease during the treatment course. 5 year disease free survival was 48%. There were 2 independent prognostic factors for DFS and OS: Clinical stage (I, II vs. III, IV) (p = 0.005 and p = 0.007) and accomplishment of treatment (p = 0.014 and p = 0.011). There was no prognostic value of histological subtype. A marginally significant difference in DFS and OS is apparent between chemotherapy only (CT) and combined modality treatment (CMT) groups (p = 0.005 and p = 0.06). No significant difference was found between CT and radiotherapy only (RT) or CMT and RT treatment groups. However there is little covariation of clinical stage between CT or CMT and RT groups. The treatment was in general well tolerated with a very low rate of severe complications and no treatment related death.

#### Conclusions:

- (1) With our less aggressive approach we achieved results comparable to those found in the literature while the tolerance of treatment was better compared to the studies employing more aggressive regimens.
- (2) Our results indicate that less aggressive CHT approach may be compensated by addition of RT in favour of compliance in elderly patients with HD.

1341

POSTER

### Bcl-6 gene alterations in non-Hodgkin's lymphomas

P.M. Chen, Y.C. Lin, C.J. Chu, F.S. Fan, T.J. Chiou, J.H. Liu. Section of Medical Oncology, Veterans General Hospital-Taipei and National Yang-Ming University, Taipei, Taiwan, China

**Purpose:** In the Western, rearrangements and point mutation (PM) of Bcl-6 gene can be identified in 20–40% and 70% of diffuse large-cell lymphomas (DLCLs). However, there are few reports concerning Bcl-6 gene alterations in Chinese non-Hodgkin's lymphoma (NHL) patients.

**Methods:** Lymph node samples obtained from 155 patients with NHLs (70 patients with DLCLs) were examined for the presence of gene rearrangements (GR) and PM in the Bcl-6 proto-oncogene using Southern blot analysis and single-strand conformation polymorphism followed by sequence analysis, the histopathologic classification with clinical outcome was then assessed.

**Results:** GR and PM in 155 NHL patients were 16.7% (n = 25) and 29.7% (n = 46) respectively. Meanwhile, in 70 DLCLs, Bcl-6 GR were identified in 13 (18.6%) and PM in 27 (38.6%). Bcl-6 PM occurred independently of Bcl-6 GR. All of Bcl-6 GR in NHLs were of the B-cell type, whereas 3 PM were derived from the T-cell lineage including a case of adult T-cell lymphoma. By Cox's proportional hazard model for risk factor, these two types of gene alterations in DLCLs or in all NHLs were not associated exclusively with extranodal sites and were not a prognostic predict.

**Conclusion:** The incidence of Bcl-6 alterations in DLCLs is lower in Taiwan than of in the Western. Clinically, these two types of gene alterations in DLCLs or in all NHLs did not appear to carry any prognostic significance.

1342

POSTER

### Increase of the myelodysplastic syndrome (MDS) incidence in Chernobyl-contaminated regions of Belarus can be the first evidence of radiation-dependent leukaemogenesis

V.E. Ivanov, G.V. Tolochko, L.P. Shuvaeva, E.P. Ivanov. Institute of Haematology and Blood Transfusion, Minsk, Belarus

In 1986–1992 Belarussian National Registry of Blood Disorders was created in our Institute. It covers 7 years before Chernobyl and all post Chernobyl period. During this years all cases of leukaemia and MDS were collected and analysed, and only from 1996 we were able to establish some disturbances, that seems to be radiation-dependent.

In the years 1996–1997 the increase of MDS among adults, who lives on the Chernobyl-contaminated territories of Belarus, has been found. The incidence for whole Belarus in 1996–1997 was 0.9 per 100.000 population and in contaminated Mogilev region it was 1.32 in 1996 and 3.04 per 100.000 population in 1997. The same picture was evidenced in other contaminated Gomel region: 1.53 in 1996 and 1.05 per 100.000 population in 1997. The FAB classification was introduced in Belarus since 1990 in